<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463488</url>
  </required_header>
  <id_info>
    <org_study_id>TDU11685</org_study_id>
    <secondary_id>2011-003232-31</secondary_id>
    <secondary_id>U1111-1121-3831</secondary_id>
    <secondary_id>TDU11685/ACT12505</secondary_id>
    <nct_id>NCT01463488</nct_id>
  </id_info>
  <brief_title>Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part I</brief_title>
  <official_title>A Two Part Protocol to Assess, Using Double Blind Placebo Control, the Safety, Tolerability, and Pharmacokinetics of Ascending Single Doses of a New Intra-articular Administration Formulation of SAR113945 (IKK Inhibitor) Followed by Assessment of Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objectives:

        -  Part 1 TDU11685 To assess in patients with knee Osteoarthritis (OA), the safety,
           tolerability and pharmacokinetics (PK) of single intra-articular doses of SAR113945.

        -  Part 2 ACT12505 To assess in patients with knee OA, the efficacy, safety and
           tolerability of a single intra-articular dose of SAR113945.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - Screening will be performed within 28 days of dosing. Following the single dose of study
      medication, the study period for each patient will be 168 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain, Stiffness and Physical Function sub-scales from the WOMAC Index</measure>
    <time_frame>during 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients reporting Adverse Events of special interest: tolerability at the site of injection and in the knee + other events reported by the patient</measure>
    <time_frame>during 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>during 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC)</measure>
    <time_frame>during 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (t1/2)</measure>
    <time_frame>during 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>synovial fluid levels</measure>
    <time_frame>during 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>SAR113945 - Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR113945 - Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR113945 - Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR113945</intervention_name>
    <description>Pharmaceutical form:Injection
Route of administration: Intra-articular</description>
    <arm_group_label>SAR113945 - Dose 1</arm_group_label>
    <arm_group_label>SAR113945 - Dose 2</arm_group_label>
    <arm_group_label>SAR113945 - Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:Injection
Route of administration: Intra-articular</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Diagnosis of primary knee osteoarthritis, based upon the following:

          -  X-ray or Magnetic Resonance Imaging (MRI) evidence within the last 6 months for joint
             space narrowing and osteophyte formation

          -  Patients will be Kellgren and Lawrence classification II/III, and total Western
             Ontario McMaster (WOMAC) score 24 -72.

          -  Patients fulfilling the American College of Rheumatology Clinical and Radiographic
             criteria for Osteoarthritis.

        Exclusion criteria:

          -  Patients younger than 40 years

          -  Women of child bearing potential.

          -  Women either sterilized for more than 3 months, or post-menopausal for more than 12
             months. Menopause is defined as over age of 60 years or being amenorrheic for at least
             2 years with plasma FSH level &gt;30 IU/L.

          -  Secondary osteoarthritis: e.g., autoimmune disease, joint dysplasia, aseptic
             osteonecrosis, acromegaly, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease,
             Stickler's syndrome, joint infection, haemophilia, haemochromatosis, calcium
             pyrophosphate deposition disease, or neuropathic arthropathy.

          -  Presence of local skin abnormality at the affected knee joint.

          -  Intra-articular injection within 3 months.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2011</study_first_submitted>
  <study_first_submitted_qc>October 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2011</study_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

